US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Lipidor publishes interim report for H1 2021

STOCKHOLM, Sweden, 24[th] August 2021: Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – June 2021. The quarterly report is available on the company's website (click here ) and in the attached pdf (in Swedish).Summary of the interim report – second quarter 2021 Lipidor has had an intense first half year with success in many areas. At the beginning of the year, we signed a license agreement with Cannassure Therapeutics (for topical medical cannabis products based on

Summer letter from Lipidor

STOCKHOLM, Sweden, 6 July 2021: CEO Ola Holmlund comments on the year’s progress so far and the recent commercial license agreement with the Menarini Group’s subsidiary RELIFE.The first half of this year has been an intensive period in several areas. In the beginning of the year, we signed a license agreement with Cannassure Therapeutics (for topical medical cannabis products based on Lipidor’s AKVANO® technology) as well as submitted an application regarding the start of the Phase III clinical trial with our combination drug candidate for the treatment of psoriasis (AKP02). Furthermore,

Lipidor publishes interim report for Q1 2021

STOCKHOLM, Sweden, 6 May 2021: Today, Lipidor AB (publ) (Nasdaq First North: LIPI) publishes its interim report for the period January – March 2021. The quarterly report is available on the company's website (click here ) and in the attached pdf (in Swedish).Summary of the interim report – first quarter 2021 The period began with a signed license agreement with Cannassure Therapuetics Ltd, regarding medical cannabis products based on Lipidor's AKVANO® technology. Activities prior to the start of the Phase III study with AKP02, and

Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova

Stockholm, Sweden, 23 April 2021 – Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health market, will gather data for the upcoming launch.Emollivet develops animal care products based on Lipidor's patented AKVANO technology. The company was funded in 2020 to focus on commercializing animal care products. Since Stina Linge was recruited as CEO last autumn, development in Emollivet has accelerated.

Correction: Lipidor publishes interim report for H1 2020

In the last press release, Lipidor published that the information and interim report was such that Lipidor is required to publish under the EU Market Abuse Regulation. This was incorrect as the interim report for H1 2020 contains no insider information. This has been corrected in this press release.Today, Lipidor AB publishes its interim report for the period January - June 2020. The quarterly report is available on the company's website lipidor.se  and in the attached pdf. Summary of the interim report – second quarter 2020

Lipidor publishes interim report for H1 2020

Today, Lipidor AB publishes its interim report for the period January - June 2020. The quarterly report is available on the company's website lipidor.se  and in the attached pdf.Summary of the interim report – second quarter 2020 Lipidor has continuous positive ongoing out-licensing discussions with potential licensees. Preperations for initiation of the phase lll-study in AKP02 continues according to plan. The planned study is fully financed from existing funds. The subsidiary Emollivet AB, operational within Animal-

Resolutions from Lipidor’s Extraordinary General Meeting

Today, 11 August 2020, Lipidor AB (publ) (the “Company” or “Lipidor”) held an extraordinary general meeting (“EGM”) in Solna, Sweden. The EGM resolved upon, inter alia, the following resolutions.Resolution on approval of the Company’s subsidiary Emollivet AB’s (the “Subsidiary” or “Emollivet”) resolution on a new issue of shares The EGM resolved unanimously to approve the Subsidiary’s resolution of 30 June 2020 on a new issue of at most 800 shares in the Subsidiary with deviation from the shareholders’ pre-emption rights (the “New Issue”). The subscription price amounts to SEK 5,000 per

Lipidor AB (publ) announces subsidiary Emollivet AB’s recruitment of Stina Linge as CEO

Lipidor AB ("Lipidor") today announces that the subsidiary Emollivet AB ("Emollivet") has recruited Stina Linge as CEO. Stina Linge joins Emollivet from her most recent role as Head of Startup Programs at Chalmers Ventures. Stina will take up her position on September 2, 2020.Lipidor recently announced an updated plan to increase the rate of commercialization of its subsidiary Emollivet's products for animal applications. A licensing agreement formalizing the relationship between Emollivet and Lipidor has been signed and a directed new share issue proposal in Emollivet has been presented,

NOTICE OF EXTRAORDINARY GENERAL MEETING OF LIPIDOR AB (publ)

The shareholders of Lipidor AB (publ) (the "Company") are hereby invited to attend an Extraordinary General Meeting on August 11, 2020 at 11:00 a.m. CET. 13.00 at Karolinska Institutet Science Park, Fogdevreten 2 in Solna. Voting rights registration begins at 12.30 p.m. and will cease when the meeting is opened.The Company continues to closely monitor the situation in relation to Covid-19, the coronavirus, and shall return with further information closer to the date of the EGM if it is deemed necessary to take any special precautions against contamination in connection with the holding of

Lipidor AB (publ) formalizes relationship with subsidiary Emollivet AB through license agreement and proposes financing of subsidiary

Lipidor AB ("Lipidor" or the “Company") and its subsidiary Emollivet AB ("Emollivet") have formalized the relationship by entering into a licence agreement that regulates the right to Lipidor's patented AKVANO® technology. On June 30, Emollivet's Extraordinary General Meeting resolved on a directed new share issue of SEK 4 million, conditional on the approval of Lipidor's Extraordinary General Meeting. Emollivet also intends to recruit a CEO, and Emollivet’s EGM has decided to issue warrants in Emollivet to this person, subject to the approval of Lipidor's EGM. Notice of the Extraordinary

There are no items matching the current filter
There are no more items matching the current filter
Back to top